EMA/94140/2021

European Medicines Agency decision

P/0101/2021

of 17 March 2021

on the agreement of a paediatric investigation plan for tacrolimus (EMEA-001642-PIP02-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0101/2021

of 17 March 2021

on the agreement of a paediatric investigation plan for tacrolimus (EMEA-001642-PIP02-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Proveca Pharma Limited on 24 March 2020 under Article 16(1) of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 January 2021, in accordance with Article 17 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

Has adopted this decision:

Article 1

A paediatric investigation plan for tacrolimus, age-appropriate dosage form, oral use, gastric use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

This decision is addressed to Proveca Pharma Limited, Marine House, Clanwilliam Place, Dublin 2, Dublin, Ireland.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

EMA/PDCO/702920/2020
Amsterdam, 29 January 2021

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan

EMEA-001642-PIP02-20

Scope of the application

Active substance(s):

Tacrolimus

Condition(s):

Prevention of solid organ transplant rejection

Treatment of solid organ transplant rejection

Pharmaceutical form(s):

Age-appropriate dosage form

Route(s) of administration:

Oral use

Gastric use

Name/corporate name of the PIP applicant:

Proveca Pharma Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Proveca Pharma Limited submitted for agreement to the European Medicines Agency on 24 March 2020 an application for a paediatric investigation plan for the above mentioned medicinal product.

The procedure started on 30 April 2020.

Supplementary information was provided by the applicant on 23 October 2020. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition:

Prevention of solid organ transplant rejection

2.1.1. Indication(s) targeted by the PIP

Prophylaxis of transplant rejection in liver, kidney or heart allograft recipients (children from birth to less than 18 years of age).

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Age-appropriate dosage form.

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	2	**Study 1 (PRO/TAC/001)** Development of a liquid and/or a solid tacrolimus formulation suitable for oral administration in the paediatric population from birth to less than 18 years. **Study 2 (PRO/TAC/002)** Study to assess compatibility of the age-appropriate formulation with various feeding tubes and foods.
Non-clinical studies	0	Not applicable.
Clinical studies	2	**Study 3 (PRO/TAC/003)** Randomised, three-period, three-treatment, six-sequence, single dose, crossover study to assess bioavailability of the new age-appropriate oral formulation relative to two authorised formulations in healthy fasting adults.

Area	Number of measures	Description
		Study 4 (PRO/TAC/004) Study to compare palatability and acceptability of the new age-appropriate oral tacrolimus formulation to that of an existing similar formulation in children from 4 years to less than 12 years of age.
Extrapolation, modelling and simulation studies	1	**Study 5 (PRO/TAC/005)** Modelling and simulation study to determine paediatric dosing of the new oral tacrolimus formulation using literature and relative bioavailability data.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

2.2. Condition

Treatment of solid organ transplant rejection

2.2.1. Indication(s) targeted by the PIP

Treatment of allograft rejection resistant to treatment with other immunosuppressive medical products in children from birth to less than 18 years of age.

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.2.3. Pharmaceutical form(s)

Age-appropriate dosage form.

2.2.4. Measures

Area	Number of measures	Description
Quality-related studies	2	**Study 1 (PRO/TAC/001)** *Same as for condition: Prevention of solid organ transplant rejection.* **Study 2 (PRO/TAC/002)** *Same as for condition: Prevention of solid organ transplant rejection.*
Non-clinical studies	0	Not applicable.

Area	Number of measures	Description
Clinical studies	2	**Study 3 (PRO/TAC/003)** *Same as for condition: Prevention of solid organ transplant rejection.* **Study 4 (PRO/TAC/004)** *Same as for condition: Prevention of solid organ transplant rejection.*
Extrapolation, modelling and simulation studies	1	**Study 5 (PRO/TAC/005)** *Same as for condition: Prevention of solid organ transplant rejection.*
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By June 2023
Deferral for one or more measures contained in the paediatric investigation plan:	No